ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2216

Detection of Left Ventricular Regional Function in Primary Sjögren’s Syndrome Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging

Atsuma Nishiwaki1, Natsumi Ikumi2, Hitomi Kobayashi3,4, Yasuyuki Kobayashi5, Isamu Yokoe4, Yosuke Nagasawa6, Kaita Sugiyama6, Takamasa Nozaki6, Mitsuhiro Iwata4, Noboru Kitamura4 and Masami Takei4, 1Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 2Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 3Advanced Biomedical Imaging Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, 4Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 5Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, 6Nihon University School of Medicine, Tokyo, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: magnetic resonance imaging (MRI) and tracking, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Imaging of Rheumatic Diseases Poster III: Other Modalities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

The risk of major cardiovascular (CV) events and the long-term CV outcome in patients with primary Sjögren’s syndrome (pSS) remain unclear. Myocardial disease is typically clinically silent, only manifesting as myocardial dysfunction after an extended preclinical phase. Feature-tracking (FT) cardiac magnetic resonance (CMR) imaging can reliably be used to assess myocardial function in patients with early dysfunction. Left ventricular (LV) global longitudinal peak systolic strain (GLS) is prognostic of adverse cardiovascular outcomes in various patient populations. Global circumferential peak systolic strain (GCS) is a predictor of congestive heart failure. We sought to measure GLS and GCS using FT-CMR in pSS patients without cardiac symptoms. Furthermore, we aimed to evaluate the association of GLS and GCS with pSS status and severity.

Methods:

pSS patients without cardiac symptoms were enrolled. Patients and with no history and/or clinical findings of systemic or pulmonary hypertension, coronary artery disease, valvular heart disease, atrial fibrillation, diabetes mellitus, or dyslipidemia underwent non-contrast CMR. Disease activity was assessed using the EULAR Sjӧgren’s Syndrome Disease Activity Index (ESSDAI). Minor salivary gland biopsy was documented in 85% of patients. Salivary gland biopsy data were classified using the focus score (FS). All subjects underwent evaluation of LV regional function, as measured by FT-CMR. GLS and GCS were calculated in the 16 segments of the whole LV. Group comparisons were made using the Wilcoxon rank sum test, Fisher’s exact test, and t-test where appropriate.

Results:

We compared 52 patients with pSS (100% women; mean age, 53.2±9.6 years). A total of 11 patients (21%) had Raynaud’s phenomenon (RP). The mean of ESSDAI was 2.5±2.6. The GCS in the RP positive group and FS≥2 group decreased more than that in the RP negative group and FS<2 group (p=0.009, p=0.008, respectively). The GCS tended to decrease in the ESSDAI≥4 group compared to the ESSDAI<4 group(p=0.057). Receiver operating characteristic curve analysis showed that GCS reliably detected RP and FS≥2 (area under the curve, 0.75 and 0.72, respectively). GCS in the pSS group was not associated with CV risk factors or other pSS status. GLS in the pSS group was not associated with CV risk factors or pSS status such as RP, FS, ESSDAI.

Conclusion:

To our knowledge, this is the first prospective study of LV regional function in pSS and the only study to explore the associations of pSS characteristics with CMR-assessed GCS and GLS. We suggest that RP, FS≥2 and ESSDAI≥4 may predict LV regional dysfunction observed in patients with pSS without cardiac symptoms. We should consider the possibility of subclinical regional function in patients with pSS, even in those with low scores for FS or ESSDAI.


Disclosure: A. Nishiwaki, None; N. Ikumi, None; H. Kobayashi, None; Y. Kobayashi, None; I. Yokoe, None; Y. Nagasawa, None; K. Sugiyama, None; T. Nozaki, None; M. Iwata, None; N. Kitamura, None; M. Takei, None.

To cite this abstract in AMA style:

Nishiwaki A, Ikumi N, Kobayashi H, Kobayashi Y, Yokoe I, Nagasawa Y, Sugiyama K, Nozaki T, Iwata M, Kitamura N, Takei M. Detection of Left Ventricular Regional Function in Primary Sjögren’s Syndrome Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/detection-of-left-ventricular-regional-function-in-primary-sjogrens-syndrome-patients-without-cardiac-symptons-as-assessed-by-feature-tracking-cardiac-magnetic-resonance-imaging/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/detection-of-left-ventricular-regional-function-in-primary-sjogrens-syndrome-patients-without-cardiac-symptons-as-assessed-by-feature-tracking-cardiac-magnetic-resonance-imaging/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology